GlassScriptPhysician profile
Simarpreet Kaur Vidwan
NPI 1639305444
$10,062.58
in general payments reported to CMS, 2019-2025
59 companies · $2,499 in 2025
The $2,499 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.10 · 2020: $196 · 2021: $777 · 2022: $1,712 · 2023: $2,115 · 2024: $2,681 · 2025: $2,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,265 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,264.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,047.82 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $747.40 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $695.30 | 2020-2025 | Xifaxan, Trulance, Relistor |
| Lilly USA, LLC | $677.92 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Antares Pharma, INC. | $617.34 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Glaxosmithkline, LLC. | $483.98 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $285.14 | 2022-2025 | |
| Amgen INC. | $263.44 | 2020-2025 | Repatha, Otezla, Repatha |
| Cequr Corporation | $242.82 | 2024-2025 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.80 | 2023-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Esperion Therapeutics, INC. | $220.70 | 2021-2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $216.29 | 2020-2025 | Rexulti |
| Pfizer INC. | $210.12 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $209.12 | 2023-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $196.82 | 2021-2025 | Breztri, Airsupra, Farxiga |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simarpreet Vidwan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.